So should Vaxcyte (NASDAQ:PCVX) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn ...

We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential. In this ...

Here are two such growth stocks that Wall Street rates as a “Strong Buy” and believes will generate more than 300% returns ...

In its fourth quarter 2024 investor letter, Carillon Eagle Small Cap Growth Fund emphasized stocks such as Vaxcyte, Inc. (NASDAQ:PCVX). Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology ...

Shares of PCVX opened at $31.20 on Friday. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The firm has a market capitalization of $4.02 billion, a P/E ratio of ...

Vaxcyte (NASDAQ:PCVX – Free Report) had its price target cut by The Goldman Sachs Group from $138.00 to $100.00 in a report released on Tuesday,Benzinga reports. They currently have a buy rating on ...

We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look at where Vaxcyte, Inc. (NASDAQ:PCVX) stands against the other debt free mid ...

Vaxcyte PCVX is a clinical-stage biotech focused on developing vaccines to prevent or treat bacterial infectious diseases. In the past month, PCVX's shares have nosedived 56%. This downside came ...